Synthesis of new arylisoxazole-oxindole conjugates as potent antiproliferative agents

Gajjela Bharath Kumar, Bukhari Syed Nasir Abbas, Hua Li Qin

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A new series of arylisoxazole-oxindole derivatives (6a-r) were synthesized and evaluated for their antiproliferative activity against human cancer cell lines including non-small cell lung (A549), cervical (HeLa), breast (MCF-7), and prostate (DU-145) cancer cell lines. The synthesized compounds (6a-r) demonstrated excellent to moderate cytotoxicity with IC50 values ranging from 0.82 to 3.69 μm. Some new compounds (6m-r) exhibited profound cytotoxicity better or similar to positive control. More particularly, the compound 6q possesses donating substituent like methoxy group presented at 5-position on D ring exhibited remarkable antiproliferative activity against A-549 (lung cancer) with an IC50 value 0.82 μm. Further studies to determine the mechanistic aspects of these conjugates are under progress.

Original languageEnglish
JournalChemical Biology and Drug Design
DOIs
Publication statusAccepted/In press - 2016
Externally publishedYes

Fingerprint

Inhibitory Concentration 50
Cells
Cytotoxicity
Cell Line
Human Activities
Prostate
Lung Neoplasms
Neoplasms
Breast
Lung
Derivatives
oxindole
A549 Cells

Keywords

  • Antiproliferative activity
  • Arylisoxazole-oxindole
  • Cancer
  • Drug discovery
  • Nocodazole

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine

Cite this

Synthesis of new arylisoxazole-oxindole conjugates as potent antiproliferative agents. / Kumar, Gajjela Bharath; Syed Nasir Abbas, Bukhari; Qin, Hua Li.

In: Chemical Biology and Drug Design, 2016.

Research output: Contribution to journalArticle

@article{3b3888a63e9744ebad01598214ab39ca,
title = "Synthesis of new arylisoxazole-oxindole conjugates as potent antiproliferative agents",
abstract = "A new series of arylisoxazole-oxindole derivatives (6a-r) were synthesized and evaluated for their antiproliferative activity against human cancer cell lines including non-small cell lung (A549), cervical (HeLa), breast (MCF-7), and prostate (DU-145) cancer cell lines. The synthesized compounds (6a-r) demonstrated excellent to moderate cytotoxicity with IC50 values ranging from 0.82 to 3.69 μm. Some new compounds (6m-r) exhibited profound cytotoxicity better or similar to positive control. More particularly, the compound 6q possesses donating substituent like methoxy group presented at 5-position on D ring exhibited remarkable antiproliferative activity against A-549 (lung cancer) with an IC50 value 0.82 μm. Further studies to determine the mechanistic aspects of these conjugates are under progress.",
keywords = "Antiproliferative activity, Arylisoxazole-oxindole, Cancer, Drug discovery, Nocodazole",
author = "Kumar, {Gajjela Bharath} and {Syed Nasir Abbas}, Bukhari and Qin, {Hua Li}",
year = "2016",
doi = "10.1111/cbdd.12884",
language = "English",
journal = "Chemical Biology and Drug Design",
issn = "1747-0277",
publisher = "Blackwell",

}

TY - JOUR

T1 - Synthesis of new arylisoxazole-oxindole conjugates as potent antiproliferative agents

AU - Kumar, Gajjela Bharath

AU - Syed Nasir Abbas, Bukhari

AU - Qin, Hua Li

PY - 2016

Y1 - 2016

N2 - A new series of arylisoxazole-oxindole derivatives (6a-r) were synthesized and evaluated for their antiproliferative activity against human cancer cell lines including non-small cell lung (A549), cervical (HeLa), breast (MCF-7), and prostate (DU-145) cancer cell lines. The synthesized compounds (6a-r) demonstrated excellent to moderate cytotoxicity with IC50 values ranging from 0.82 to 3.69 μm. Some new compounds (6m-r) exhibited profound cytotoxicity better or similar to positive control. More particularly, the compound 6q possesses donating substituent like methoxy group presented at 5-position on D ring exhibited remarkable antiproliferative activity against A-549 (lung cancer) with an IC50 value 0.82 μm. Further studies to determine the mechanistic aspects of these conjugates are under progress.

AB - A new series of arylisoxazole-oxindole derivatives (6a-r) were synthesized and evaluated for their antiproliferative activity against human cancer cell lines including non-small cell lung (A549), cervical (HeLa), breast (MCF-7), and prostate (DU-145) cancer cell lines. The synthesized compounds (6a-r) demonstrated excellent to moderate cytotoxicity with IC50 values ranging from 0.82 to 3.69 μm. Some new compounds (6m-r) exhibited profound cytotoxicity better or similar to positive control. More particularly, the compound 6q possesses donating substituent like methoxy group presented at 5-position on D ring exhibited remarkable antiproliferative activity against A-549 (lung cancer) with an IC50 value 0.82 μm. Further studies to determine the mechanistic aspects of these conjugates are under progress.

KW - Antiproliferative activity

KW - Arylisoxazole-oxindole

KW - Cancer

KW - Drug discovery

KW - Nocodazole

UR - http://www.scopus.com/inward/record.url?scp=85004191386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85004191386&partnerID=8YFLogxK

U2 - 10.1111/cbdd.12884

DO - 10.1111/cbdd.12884

M3 - Article

JO - Chemical Biology and Drug Design

JF - Chemical Biology and Drug Design

SN - 1747-0277

ER -